drugset / Trial / NCT00386516

Study to Test the Benefit and Safety of GM-CT-01 in Combination With 5-FU to Treat Bile Duct and Gall Bladder Cancer

NCT00386516

Phase 2 Withdrawn Galectin Therapeutics Inc.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this clinical trial is to determine whether the combination of the established chemotherapeutic agent 5-fluorouracil(5-FU) and the large carbohydrate molecule GM-CT-01 is beneficial in treating advanced gall bladder and bile duct cancer.

Timeline

Start
2006-09
Primary completion
2009-06
Completion
2009-06

Drugs

EvaluationDrugModalityDoseRoute
Subject DAVANAT Other / unclassified 280 mg/m2 Intravenous
Background fluorouracil Small molecule 600 mg/m2 Intravenous